CurrentBlue Cross Blue Shield - MassachusettsPolicy 576

Myocardial sympathetic innervation imaging with 123I‑MIBG

Policy governing coverage and authorization for myocardial sympathetic innervation imaging using iodine-123 metaiodobenzylguanidine (123I-MIBG) for individuals with heart failure; defines investigational stance and prior authorization requirements for inpatient services and noncoverage for outpatient settings.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyMyocardial sympathetic innervation imaging with 123I‑MIBG

Policy CodePolicy 576

Change TypeNo material change

Effective Date

Next Review Date

Key ActionPrecertification/preauthorization is required for all products when the procedure is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalCoverage stance

Prior auth (inpatient)Inpatient authorization

Not coveredOutpatient status

0331T,0332T,A9582Listed codes

No demonstrated clinical utilityEvidence summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations

Overall coverage stance

Policy statements and evidence summary

Primary coverage stance: Myocardial sympathetic innervation imaging with 123I‑MIBG is investigational for use in individuals with heart failure.

Investigational for all diagnoses; evidence shows prognostic association but insufficient evidence of clinical utility.

Outpatient coverage: Outpatient imaging for this service is not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM.

Explicit noncoverage statement for outpatient settings.

Inpatient authorization: Precertification/preauthorization is required for all products if the procedure is performed inpatient.

Authorization requirement applies despite investigational stance and may be used to trigger denials for inpatient procedures.

Evidence summary: Studies show 123I‑MIBG imaging predicts adverse cardiac events and improves risk prediction models, but there is insufficient direct evidence that using MIBG to guide management improves health outcomes.

No chain of evidence demonstrating clinical utility; net health benefit not established.

For outpatient settings the policy explicitly states that myocardial sympathetic innervation imaging with 123I‑MIBG is not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM members. Providers should note that this noncoverage applies to outpatient performance of the service regardless of diagnosis or indication.

The reference section of the policy contains literature citations, prescribing information, and guidelines but does not list additional explicit coverage exclusions beyond the outpatient noncoverage statement. These references are presented for background and evidentiary support and do not themselves specify coverage decisions or exclusionary entries.

Myocardial sympathetic innervation imaging with 123I‑MIBG is designated investigational for use in individuals with heart failure because, although numerous studies demonstrate that MIBG parameters predict adverse cardiac events and can improve prognostic models, there is insufficient evidence of clinical utility. Specifically, no published studies establish that test results lead to management changes that improve health outcomes, and a chain of evidence supporting net health benefit cannot be constructed.

The References section lists FDA prescribing information and multiple prognostic studies and meta-analyses but does not identify any items as not medically necessary. The citations are provided to support clinical context and evidence review rather than to assert additional non‑medical‑necessity listings.

Procedure and Billing Codes

CPT CodesCPT

0331T	Myocardial sympathetic innervations imaging, planar qualitative and quantitative assessment;
0332T	Myocardial sympathetic innervations imaging, planar qualitative and quantitative assessment; with tomographic SPECT

HCPCS CodesHCPCS

A9582

Iodine I-123 iobenguane, diagnostic, per study dose, up to 15 millicuries

Diagnosis CodesICD-10Not Covered

No codes listed

Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Required for Inpatient

For services described in this policy, precertification/preauthorization is required for all products when the procedure is performed inpatient.

Applies to all inpatient settings across products

Note

Prior Authorization Not Specified for Outpatient

This section does not specify any prior authorization requirements for outpatient services. Providers should check product-specific benefit documents or contact the plan for outpatient prior authorization requirements, as this section only details inpatient preauthorization.

Prior authorization not specified in this section for outpatient services

Clinical Background and Rationale

Heart failure is associated with activation of the sympathetic nervous system, increased norepinephrine release, and reduced neuronal reuptake, pathophysiologic changes that can worsen myocardial damage and increase arrhythmic risk. Iodine‑123 metaiodobenzylguanidine (123I‑MIBG) is a radiolabeled analogue that concentrates in sympathetic nerve endings and can be imaged to assess myocardial sympathetic innervation. Studies have used quantitative measures such as heart‑to‑mediastinum ratios and washout rates, and multiple cohort studies and trials have shown that abnormal MIBG findings are associated with worse prognosis in heart failure; however, the absence of demonstrated clinical utility limits its role in routine management.

Terms and Device/Product Definitions

Iodine-123 metaiodobenzylguanidine (MIBG) — description and quantitation metrics

Agent descriptionIodine-123 metaiodobenzylguanidine (123I-MIBG) is a chemically modified guanethidine analogue labeled with radioactive iodine that concentrates in myocardial sympathetic nerve endings and can be imaged with a conventional gamma camera.

Mechanism of myocardial uptakeMIBG is taken up via the neuronal uptake-1 pathway into presynaptic nerve terminals and is stored without catabolism, so myocardial concentration reflects sympathetic neuronal activity.

Common quantitative metricsEarly heart-to-mediastinum (H/M) ratio, late H/M ratio, and myocardial MIBG washout rate are the most commonly used indices.

How H/M ratio is calculatedH/M ratio = average counts per pixel in myocardium divided by average counts per pixel in the mediastinum on planar anterior views.

Washout rate definitionMyocardial washout rate = rate of decrease in myocardial counts between early and late images, normalized to mediinal activity.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyMyocardial sympathetic innervation imaging with 123I‑MIBG

Policy CodePolicy 576

Change TypeNo material change

Effective Date

Next Review Date

Key ActionPrecertification/preauthorization is required for all products when the procedure is performed inpatient.

SourceLink

On This Page

Denial Risk

Outpatient Services Not Covered

Outpatient myocardial sympathetic innervation imaging with 123I-MIBG is not a covered service across products listed. Do not bill as covered outpatient service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, or Medicare PPO Blue SM.

Commercial Managed Care (HMO and POS), Outpatient = Not a covered service
Commercial PPO and Indemnity, Outpatient = Not a covered service
Medicare HMO Blue SM, Outpatient = Not a covered service
Medicare PPO Blue SM, Outpatient = Not a covered service

Documentation Required

Coding and Documentation Requirements

Providers should report all services using the most up-to-date procedure, revenue, and diagnosis codes (including modifiers where applicable). The CPT and HCPCS codes listed in this policy are for informational purposes and their presence does not guarantee coverage.

Include relevant CPT (0331T, 0332T) and HCPCS (A9582) codes where applicable for informational reporting
Diagnosis codes: Investigational for all diagnoses

Note

References (Informational)

References provided (FDA prescribing information for AdreView and multiple prognostic studies) support clinical context but do not establish outpatient coverage; they may inform medical necessity discussions.

FDA AdreView prescribing information (2020)
Multiple prognostic and utility studies (ADMIRE-HF and pooled analyses)

AdreView (Iobenguane I 123 Injection) — FDA‑approved radiopharmaceutical product reference

Product nameAdreView (Iobenguane I 123 Injection)

Regulatory statusReferenced FDA Highlights of Prescribing Information for intravenous use (AdreView).

Source citationFDA prescribing information: AdreView (Iobenguane I 123 Injection), 2020.

123I‑MIBG imaging — definition and common uses in prognostic assessment

DefinitionMyocardial scintigraphic imaging of sympathetic innervation using iodine-123 metaiodobenzylguanidine (123I-MIBG).

Typical imaging protocolPlanar thoracic images obtained early (~15 minutes) and late (~4 hours) after slow IV injection; optional SPECT can follow early and late planar images.

Clinical uses reportedStudied as a prognostic marker in heart failure to identify patients at increased short-term mortality risk and to guide treatment decisions or monitor therapy effectiveness; evidence shows prognostic association but insufficient demonstration of improved outcomes.

Standardization noteNo single universally used myocardial MIBG index; standardized procedures have been proposed by European organizations.